Novartis will make waves in gene therapy, says head of biomedical research
This article was originally published in Scrip
Novartis, unlike several of its big pharma peers, has itself a healthy looking pipeline now and for the foreseeable future – allowing the company the luxury of "being a bit choosy" when it comes to selecting investments.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.